Abstract
In the past few years, ovarian cancer research has focused increasingly on disease prevention; but an increasing number of women refer to gynecology and clinical genetics clinics with a family history of ovarian cancer and inherited familial mutations. The interest on the issue has increased also due to the identification of BReast CAncer1 (BRCA1) and BRCA2 genes mutations. The importance of recognizing the characteristics of hereditary ovarian cancer (HOC) and manage women at risk appropriately will provide more accurate care of the high-risk population. Women at risk can be identified by pedigree analysis and may receive counseling from interdisciplinary cancer genetics clinics, while those at high risk need to receive genetic testing. Risk calculation programs define risks and assist in decision-making in clinical options and genetic testing; they provide information on the risks of the disease, mutation status, and the use of genetic testing in the management of high-risk families. Furthermore, while a large number of surrogate preliminary markers have been identified, there are still limited studies on ovarian cancer genomics. Different options for risk management of HOC are available: surveillance, chemoprevention and prophylactic surgery. Surveillance in HOC high-risk patients is still not accurate. Chemoprevention is currently a controversial topic, because a number of major issues still need to be addressed in developing and testing agents for ovarian cancer chemoprevention. Prophylactic surgery has been shown to effectively decrease cancer risk, and it has the possibility to substantially reduce ovarian cancer mortality.
Similar content being viewed by others
References
Tinelli, A., Vergara, D., Martignago, R., Leo, G., Pisanò, M., & Malvasi, A. (2009). An outlook on ovarian cancer and borderline ovarian tumors: focus on genomic and proteomic findings. Current Genomics, 4(10), 240–249.
Sankaranarayanan, R., & Ferlay, J. (2006). Worldwide burden of gynaecological cancer: the size of the problem. Best Practice & Research Clinical Obstetrics Gynaecology, 20, 207–225.
Lynch, H. T., Snyder, C. L., Lynch, J. F., Riley, B. D., & Rubinstein, W. S. (2003). Hereditary breast-ovarian cancer at the bedside: role of the medical oncologist. Journal of Clinical Oncology, 21, 740–753.
Lynch, H. T., Krush, A. J., Lemon, H. M., et al. (1972). Tumor variation in families with breast cancer. Jama, 222, 1631–1635.
Nielsen, F. C., Kruse, T. A., & Gerdes, A. M. (2008). BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer. Acta Oncologica, 47(4), 772–777.
Sinilnikova, O. M., Mazoyer, S., Bonnardel, C., Lynch, H. T., Narod, S. A., & Lenoir, G. M. (2006). BRCA1 and BRCA2 mutations in breast and ovarian cancer syndrome: reflection on the Creighton University historical series of high-risk families. Familial Cancer, 5, 15–20.
Brunet, J., & Pèrez-Segura, P. (2004). Cancer screening and genetic counselling. Reviews in oncology, 6(3), 176–183.
Ries LAG, Harkins D, Krapcho M, Mariotto A, Miller BA, Feuer ES, et al. (eds). SEER Cancer Statistics Review, 1975 – 2004, National Cancer Institute, Bethesda, http://seer.cancer.gov/csr/1975_2004/, based on November 2006 SEER data submission, posted to the SEER website 2007
Kurian, A. W., Balise, R. R., McGuire, V., & Whittemore, A. S. (2005). Histologic types of epithelial ovarian cancer: have they different risk factors? Gynecologic Oncology, 96, 520–530.
Chiaffarino, F., Parazzini, F., Bosetti, C., Franceschi, S., Talamini, R., Canzonieri, V., et al. (2007). Risk factors for ovarian cancer histotypes. European Journal of Cancer, 43, 1208–1213.
Bray, F., Loos, A. H., Tognazzo, S., & La Vecchia, C. (2005). Ovarian cancer in Europe: cross-sectional trends in incidence and mortality in 28 countries, 1953–2000. International Journal of Cancer, 113, 977–990.
Negri, E., Pelucchi, C., Franceschi, S., Montella, M., Conti, E., Dal Maso, L., et al. (2003). Family history of cancer and risk of ovarian cancer. European Journal of Cancer, 39, 505–510.
La Vecchia, C. (2001). Epidemiology of ovarian cancer: a summary review. European Journal of Cancer Prevention, 10, 125–129.
Simon, M. S., & Petrucelli, N. (2009). Hereditary breast and ovarian cancer syndrome: the impact of race on uptake of genetic counseling and testing. Methods in Molecular Biology, 471, 487–500.
Chen, Y., Farmer, A. A., Chen, C. F., Jones, D. C., Chen, P. L., & Lee, W. H. (1996). BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner. Cancer Research, 56, 3168–3172.
Ruffner, H., & Verma, I. M. (1997). BRCA1 is a cell cycle-regulated nuclear phosphoprotein. Proceedings of the National Academy of Sciences of the United States of America, 94, 7138–7143.
Deng, C. X. (2006). BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Research, 34(5), 1416–1426.
Yu, X. C., CC, He M., Mer, G., & Chen, J. (2003). The BRCT domain is a phospho-protein binding domain. Science, 302, 639–642.
Manke, I. A., Lowery, D. M., Nguyen, A., & Yaffe, M. B. (2003). BRCT repeats as phosphopeptide-binding modules involved in protein targeting. Science, 302, 636–639.
Arai, M., Utsunomiya, J., & Miki, Y. (2004). Familial breast and ovarian cancers. International Journal of Clinical Oncology, 9, 270–282.
Ouchi, T., Monteiro, A. N., August, A., Aaronson, S. A., & Hanafusa, H. (1998). BRCA1 regulates p53-dependent gene expression. Proceedings of the National Academy of Sciences of the United States of America, 95(5), 2302–2306.
Fan, S., Yong, X., Wang, C., Yuan, R. Q., Meng, Q., Wang, J. A., et al. (2001). Role of direct interaction in BRCA1 inhibition of estrogen receptor activity. Oncogene, 20(1), 77–87.
Zheng, L., Annab, L. A., Afshari, C. A., Lee, W. H., & Boyer, T. G. (2001). BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. Proceedings of the National Academy of Sciences of the United States of America, 98(17), 9587–9592.
Rajan, J. V., Wang, M., Marquis, S. T., & Chodosh, L. A. (1996). Brca2 is coordinately regulated with Brca1 during proliferation and differentiation in mammary epithelial cells. Proceedings of the National Academy of Sciences, 93, 13078–13083.
Sharan, S. K., Morimatsu, M., Albrecht, U., Lim, D. S., Regel, E., Dinh, C., et al. (1997). Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature, 386, 804–810.
Marmorstein, L. Y., Ouchi, T., & Stuart, A. A. (1998). The BRCA2 gene product functionally interacts with p53 and RAD51. Proceedings of the National Academy of Sciences of the United States of America, 95(23), 13869–13874.
Crotser, C. B., & Boehmke, M. (2009). Survivorship considerations in adults with hereditary breast and ovarian cancer syndrome: state of the science. Journal of Cancer Survival, 3(1), 21–42.
Russo, A., Calò, V., Bruno, L., Rizzo, S., Bazan, V., & Di Fede, G. (2009). Hereditary ovarian cancer. Critical Reviews in Oncology/Hematology, 69(1), 28–44.
van der Velde, N. M., Mourits, M. J., Arts, H. J., de Vries, J., Leegte, B. K., Dijkhuis, G., et al. (2009). Time to stop ovarian cancer screening in BRCA1/2 mutation carriers? International Journal of Cancer, 124(4), 919–923.
Nelson, H. D., Huffman, L. H., Fu, R., & Harris, E. L. (2005). U.S. Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force. Annals of Internal Medicine, 143(5), 362–379.
Thomassen, M., Hansen, T. V., Borg, A., Lianee, H. T., Wikman, F., Pedersen, I. S., et al. (2007). Hereditary ovarian cancer—assessing risk and prevention strategies. Obstetrics and Gynecology Clinics of North America, 34(4), 651–665.
Skinner, C. S., Schildkraut, J. M., Berry, D., Calingaert, B., Marcom, P. K., Sugarman, J., et al. (2002). Pre-counseling education materials for BRCA testing: does tailoring make a difference? Genetis Testing, 6(2), 93–105.
Peters, N., Domchek, S. M., Rose, A., Polis, R., Stopfer, J., & Armstrong, K. (2005). Knowledge, attitudes, and utilization of BRCA1/2 testing among women with early onset breast cancer. Genet Test, 9(1), 48–53.
Vadaparampil, S. T., Wey, J. P., & Kinney, A. Y. (2004). Psychosocial aspects of genetic counseling and testing. Seminars in Oncology Nursing, 20(3), 186–195.
Kehoe, S. M., & Kauff, N. D. (2007). Screening and prevention of hereditary gynecologic cancers. Seminars in Oncology, 34(5), 406–410.
Lux, M. P., Fasching, P. A., & Beckmann, M. W. (2006). Hereditary breast and ovarian cancer: review and future perspectives. Journal of Molecular Medicine, 84, 16–28.
De la Hoya, M., Diez, O., Pérez-Segura, P., et al. (2003). Pre-test prediction models of BRCA1 or BRCA2 mutation in breast/ovarian families attending familial cancer clinics. Journal of Medical Genetics, 40, 503–510.
Myers, E. R., Havrilesky, L. J., Kulasingam, S. L., Sanders, G. D., Cline, K. E., Gray, R. N., et al. (2006). Genomic tests for ovarian cancer detection and management. Evidence Report/Technology Assessment (full report), 145, 1–100.
Low, C. A., Bower, J. E., Kwan, L., & Seldon, J. (2008). Benefit finding in response to BRCA1/2 testing. Annals of Behavioral Medicine, 35(1), 61–69.
Kieran, S., Loescher, L. J., & Lim, K. H. (2007). The role of financial factors in acceptance of clinical BRCA genetic testing. Genetic Testing, 11(1), 101–110.
Herman, L. M. (2008). Clinical and Scientific Affairs Council of the AAPA. Hereditary breast and ovarian cancers. JAAPA, 21(5), 18–21.
Lacour, R. A., Daniels, M. S., Westin, S. N., Meyer, L. A., Burke, C. C., Burns, K. A., et al. (2008). What women with ovarian cancer think and know about genetic testing. Gynecologic Oncology, 111(1), 132–136.
Bakos, A. D., Hutson, S. P., Loud, J. T., Peters, J. A., Giusti, R. M., & Greene, M. H. (2008). BRCA mutation-negative women from hereditary breast and ovarian cancer families: a qualitative study of the BRCA-negative experience. Health Expectations, 11(3), 220–231.
Fields, M. M., & Chevlen, E. (2006). Ovarian cancer screening: a look at the evidence. Clinical Journal of Oncology Nursing, 10(1), 77–81.
Wakahara, F., Kikkawa, F., Nawa, A., et al. (2001). Diagnostic efficacy of tumor markers, sonography, and intraoperative frozen section for ovarian tumors. Gynecologic and Obstetric Investigation, 52, 147–152.
Woodward, E. R., Sleightholme, H. V., Considine, A. M., Williamson, S., McHugo, J. M., & Cruger, D. G. (2007). Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective. BJOG, 114(12), 1500–1509.
Bermejo-Pérez, M. J., Márquez-Calderón, S., & Llanos-Méndez, A. (2008). Cancer surveillance based on imaging techniques in carriers of BRCA1/2 gene mutations: a systematic review. British Journal of Radiology, 81(963), 172–179.
McInerney-Leo, A., Biesecker, B. B., Hadley, D. W., Kase, R. G., Giambarresi, T. R., Johnson, E., et al. (2005). BRCA1/2 testing in hereditary breast and ovarian cancer families II: impact on relationships. American Journal of Medical Genetics, 133A(2), 165–169.
Lacey, J. V., Jr., Greene, M. H., Buys, S. S., Reding, D., Riley, T. L., Berg, C. D., et al. (2006). Ovarian cancer screening in women with a family history of breast or ovarian cancer. Obstetrics and Gynecology, 108(5), 1176–1184.
Myers, E. R., Bastian, L. A., Havrilesky, L. J., Kulasingam, S. L., Terplan, M. S., Cline, K. E., et al. (2006). Management of adnexal mass. Evidence Report/Technology Assessment, 130, 1–145.
Bast, R. C., Jr., Brewer, M., Zou, C., Hernandez, M. A., Daley, M., Ozols, R., et al. (2007). Prevention and early detection of ovarian cancer: mission impossible? Recent Results in Cancer Research, 174, 91–100.
Narod, S. A., Sun, P., & Risch, H. A. (2001). Ovarian cancer, oral contraceptives, and BRCA mutations. New England Journal of Medicine, 345, 1706–1707.
Modan, B., Hartge, P., Hirsh-Yechezkel, G., et al. (2001). Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. New England Journal of Medicine, 345, 235–240.
Sabichi, A. L., Hendricks, D. T., Bober, M. A., & Birrer, M. J. (1998). Retinoic acid receptor beta expression and growth inhibition of gynaecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide. Journal of the National Cancer Institute, 90, 597–605.
Supino, R., Crosti, M., Clerici, M., et al. (1996). Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression. International Journal of Cancer, 65, 491–497.
Benbrook, D. M., Madler, M. M., Spruce, L. W., Birckbichler, P. J., Nelson, E. C., Subramanian, S., et al. (1997). Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity. Journal of Medicinal Chemistry, 40(22), 3567–3583.
Guruswamy, S., Lightfoot, S., Gold, M. A., Hassan, R., Berlin, K. D., Ivey, R. T., et al. (2001). Effects of retinoids on cancerous phenotype and apoptosis in organotypic cultures of ovarian carcinoma. Journal of the National Cancer Institute, 93, 516–525.
Lefkowitz, E. S., & Garland, C. F. (1994). Sunlight, vitamin D, and ovarian cancer mortality rates in US women. International Journal of Epidemiology, 23, 1133–1136.
Ahonen, M. H., Zhuang, Y. H., Aine, R., Ylikomi, T., & Tuohimaa, P. (2000). Androgen receptor and vitamin D receptor in human ovarian cancer: growth stimulation and inhibition by ligands. International Journal of Cancer, 86, 40–46.
Ness, R. B., & Cottreau, C. (1999). Possible role of ovarian epithelial inflammation in ovarian cancer. Journal of the National Cancer Institute, 91, 1459–1467.
Moysich, K. B., Mettlin, C., Piver, M. S., Natarajan, N., Menezes, R. J., & Swede, H. (2001). Regular use of analgesic drugs and ovarian cancer risk. Cancer Epidemiology, Biomarkers and Prevention, 10, 903–906.
Rosenberg, L., Palmer, J. R., Rao, R. S., Coogan, P. F., Strom, B. L., Zauber, A. G., et al. (2000). A case-control study of analgesic use and ovarian cancer. Cancer Epidemiology, Biomarkers and Prevention, 9, 933–937.
Cramer, D. W., Harlow, B. L., Titus-Ernstoff, L., Bohlke, K., Welch, W. R., & Greenberg, E. R. (1998). Over-the-counter analgesics and risk of ovarian cancer. Lancet, 351, 104–107.
Taketo, M. M. (1998). Cyclooxygenase-2 inhibitors in tumorigenesis (part I). Journal of the National Cancer Institute, 90, 1529–1536.
Taketo, M. M. (1998). Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). Journal of the National Cancer Institute, 90, 1609–1620.
Williams, C. S., Mann, M., & DuBois, R. N. (1999). The role of cyclooxygenases in inflammation, cancer, and development. Oncogene, 18, 7908–7916.
Murphy, G. J., & Holder, J. C. (2000). PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer. Trends in Pharmacological Sciences, 21, 469–474.
Adams, M., Montague, C. T., Prins, J. B., Holder, J. C., Smith, S. A., Sanders, L., et al. (1997). Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. Journal of Clinical Investigation, 100, 3149–3153.
Mueller, E., Sarraf, P., Tontonoz, P., Evans, R. M., Martin, K. J., Zhang, M., et al. (1998). Terminal differentiation of human breast cancer through PPAR gamma. Molecular Cell, 1, 465–470.
You, Y. N., Lakhani, V. T., & Wells, S. A., Jr. (2007). The role of prophylactic surgery in cancer prevention. World Journal of Surgery, 31(3), 450–464.
Domchek, S. M., & Rebbeck, T. R. (2007). Prophylactic oophorectomy in women at increased cancer risk. Current Opinion in Obstetrics and Gynecology, 19(1), 27–30.
ACOG Practice Bulletin No. 89. (2008). Elective and risk-reducing salpingo-oophorectomy. ObstetriciÂa ginecologiÂa, 111(1), 231–241.
Guillem, J. G., Wood, W. C., Moley, J. F., Berchuck, A., Karlan, B. Y., Mutch, D. G., et al. (2006). Offit K; ASCO; SSO. ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. Journal of Clinical Oncology, 24(28), 4642–4660.
Tinelli, A., Malvasi, A., Casciaro, S., Leo, G., Vergara, D., Pisanò, M., et al. (2007). Tailoring minimally invasive gynaecological surgery based on biogenomic findings. In S. Casciaro & B. Gersak (Eds.), New technology frontiers in minimally invasive therapies (pp. 43–62). Italy: Lupiensis Biomedical Publications. 6.
Lancaster, J. M., Powell, C. B., Kauff, N. D., Cass, I., Chen, L. M., Lu, K. H., et al. (2007). Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecologic Oncology, 107(2), 159–162.
Batista, L. I., Lu, K. H., Beahm, E. K., Arun, B. K., Bodurka, D. C., & Meric-Bernstam, F. (2008). Coordinated prophylactic surgical management for women with hereditary breast-ovarian cancer syndrome. BMC Cancer, 8, 101.
Gómez García EB, Oosterwijk JC, Timmermans M, van Asperen CJ, Hogervorst FBL, Hoogerbrugge N, et al. A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history. Breast Cancer Research. 2009;11(1): R8.
Rebbeck, T. R., Kauff, N. D., & Domchek, S. M. (2009). Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. Journal of the National Cancer Institute, 101(2), 80–87.
Greene, M. H., Piedmonte, M., Alberts, D., Gail, M., Hensley, M., Miner, Z., et al. (2008). A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study. Cancer Epidemiology, Biomarkers and Prevention, 17(3), 594–604.
Menon, U., Gentry-Maharaj, A., Hallett, R., Ryan, A., Burnell, M., Sharma, A., et al. (2009). Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncology, 10(4), 327–340.
Partridge, E., Kreimer, A. R., Greenlee, R. T., Williams, C., Xu, J. L., Church, T. R., et al. (2009). Results from four rounds of ovarian cancer screening in a randomized trial. Obstetrics and Gynecology, 113(4), 775–782.
Kurian, A. W., Sigal, B. M., & Plevritis, S. K. (2010). Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. Journal of Clinical Oncology, 28(2), 222–231.
Acknowledgment
Prof. Maria Rosaria Buri
Professional Translator/Aiic Conference Interpreter, University Researcher in Translation Studies for her professional supporting in language editing.
Authors certify that there is no actual or potential conflict of interest in relation to this article and (1) all authors of this research paper have directly participated in the planning, execution, or analysis of this study; (2) all authors of this paper have read and approved the final version submitted; (3) the contents of this manuscript have not been copyrighted or published previousl; (4) the contents of this manuscript are not now under consideration for publication elsewhere; (5) the contents of this manuscript will not be copyrighted, submitted, or published elsewhere, while acceptance by the journal is under consideration; and that (6) there are no directly related manuscripts or abstracts, published or unpublished, by any authors of this paper.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tinelli, A., Malvasi, A., Leo, G. et al. Hereditary ovarian cancers: from BRCA mutations to clinical management. A modern appraisal. Cancer Metastasis Rev 29, 339–350 (2010). https://doi.org/10.1007/s10555-010-9218-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10555-010-9218-3